RecruitingNCT07180693
Breast Cancer RElapsed in Patients Treated With Adjuvant CDK4/6 Inhibitors:
Breast Cancer RElapsed in Patients Treated With Adjuvant CDK4/6 Inhibitors: Evaluation in the Real-world Setting
Sponsor
European Institute of Oncology
Enrollment
750 participants
Start Date
Sep 29, 2025
Study Type
OBSERVATIONAL
Conditions
Summary
This is a multicenter observational study with both retrospective and prospective phase, designed to evaluate the clinico-pathologic characteristics and outcomes of patients with HR+/HER2- EBC at high risk of recurrence treated with ribociclib or abemaciclib in combination with ET in the adjuvant setting.
Eligibility
Min Age: 18 Years
Inclusion Criteria6
- Female (regardless of menopausal status) or male ≥18 years of age;
- The patient has confirmed HR+, HER2-, early-stage resected invasive breast cancer candidate to adjuvant CDK4/6 inhibitors (abemaciclib or ribociclib);
- ER and PgR positivity is defined as evidence of immunohistochemical staining ≥ 1% according to ASCO/CAP recommendations; HER2 negativity is defined as expression of the membrane protein in immunohistochemistry 0 or 1+ or with a 2+ in situ hybridization (ISH) test negative as per ASCO/CAP recommendations;
- Patients who are initiating or have initiated adjuvant treatment with a CDK4/6 inhibitor (abemaciclib or ribociclib) in combination with endocrine therapy (ET). Treatment must have started on or after January 1, 2021.
- Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2;
- Consent to data treatment according to the local regulation.
Exclusion Criteria5
- Current participation in any other HR+/HER2- EBC study with any investigational products;
- Patients who have already received adjuvant treatment with a CDK4/6 inhibitor as part of a clinical trial;
- Patients unable to comply with the requirements of the study or who, in the judge of the study physician, should not be included in the study;
- Patients with a history of previous BC, with the exception of Ductal carcinoma in situ (DCIS) treated by locoregional therapy alone ≥5 years ago;
- Patients with a history of any other cancer (except non-melanoma skin cancer or carcinoma in situ of the cervix), unless in complete remission with no therapy for a minimum of 5 years from the index date, will be excluded, as well.
Locations(18)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07180693
Related Trials
Reduce Sedentary Behavior During Cancer Treatment - the RedSedCan Study
NCT067192062 locations
CDK4/6 Inhibitors Combined With Standard Adjuvant Endocrine Therapy in High-Risk, HR+/HER2+ Early Breast Cancer Patients(CHESS)
NCT070193631 location
Retrospective Observational Study of the Safety and Toxicity Management of Abemaciclib in Combination with Adjuvant Hormone Therapy in Patients with RH+ ,HER2-nonoveramplified Breast Cancer, Real-life Data (MONARCHE29)
NCT066214591 location
Safety Assessment of Concurrent Radiotherapy and Novel Systemic Therapy for Breast Cancer
NCT061975811 location
Compare Continuation of Original Targeted Therapy With Trastuzumab Combined With Pyrotinib and Capecitabine as Postoperative Adjuvant Therapy in Non-pCR Patients With HER2 Positive Early Breast Cancer
NCT052927421 location